Clinical Trials Logo

Hodgkin's Disease clinical trials

View clinical trials related to Hodgkin's Disease.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT00129753 Withdrawn - Lymphoma Clinical Trials

Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

Start date: June 22, 2005
Phase: Phase 2
Study type: Interventional

Primary Objective: To determine the safety and efficacy of Campath-1H (Alemtuzumab) in patients with relapsed and resistant classical Hodgkin's lymphoma. Secondary Objectives: 1. To determine the duration of response and time to progression after Campath-1H therapy in this patient population. 2. To determine the effect of Campath-1H on serum IL-6, IL-10, and IL-13 levels in patients with relapsed and resistant classical Hodgkin's lymphoma.